These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 23857424

  • 1. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura.
    O'Brien KL, Price TH, Howell C, Delaney M.
    J Clin Apher; 2013 Dec; 28(6):416-21. PubMed ID: 23857424
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation.
    Stefanello B, De Paula EV, Andrade Orsi F, Comenalli Marques JF, Gasparotto Roveri E, Pereira Colella M, Castro Ozelo M, Maria Annichino-Bizzacchi J, Addas-Carvalho M.
    J Clin Apher; 2014 Dec; 29(6):311-5. PubMed ID: 24890787
    [Abstract] [Full Text] [Related]

  • 3. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM.
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study.
    Korkmaz S, Keklik M, Sivgin S, Yildirim R, Tombak A, Kaya ME, Acik DY, Esen R, Hacioglu SK, Sencan M, Kiki I, Tiftik EN, Kuku I, Okan V, Yilmaz M, Demir C, Sari I, Altuntas F, Unal A, Ilhan O.
    Transfus Apher Sci; 2013 Jun; 48(3):353-8. PubMed ID: 23602056
    [Abstract] [Full Text] [Related]

  • 5. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M.
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [Abstract] [Full Text] [Related]

  • 6. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.
    Connell NT, Cheves T, Sweeney JD.
    Transfusion; 2016 Feb; 56(2):354-9. PubMed ID: 26456149
    [Abstract] [Full Text] [Related]

  • 7. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B.
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [Abstract] [Full Text] [Related]

  • 8. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.
    Goyal J, Adamski J, Lima JL, Marques MB.
    J Clin Apher; 2013 Dec; 28(6):390-4. PubMed ID: 23857472
    [Abstract] [Full Text] [Related]

  • 9. Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura.
    Moore JC, Arnold DM, Leber BF, Clare R, Molnar GJ, Kelton JG.
    Vox Sang; 2007 Aug; 93(2):173-5. PubMed ID: 17683362
    [Abstract] [Full Text] [Related]

  • 10. Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.
    Coppo P, Froissart A, French Reference Center for Thrombotic Microangiopathies.
    Hematology Am Soc Hematol Educ Program; 2015 Aug; 2015():637-43. PubMed ID: 26637782
    [Abstract] [Full Text] [Related]

  • 11. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
    Nikolaou M, Karakantza M, Adonakis G, Theodorou G, Zoumbos N, Decavalas G.
    Med Pregl; 2012 Aug; 65(9-10):436-9. PubMed ID: 23214340
    [Abstract] [Full Text] [Related]

  • 12. Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
    Peedin AR, Park YA, Mazepa MA, Rollins-Raval MA, Brecher ME, Raval JS.
    Ther Apher Dial; 2018 Dec; 22(6):662-665. PubMed ID: 30178615
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.
    Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B, Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte.
    Br J Haematol; 2006 Jan; 132(1):66-74. PubMed ID: 16371021
    [Abstract] [Full Text] [Related]

  • 14. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S, Fujimura Y.
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [Abstract] [Full Text] [Related]

  • 15. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P, Veyradier A.
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [Abstract] [Full Text] [Related]

  • 16. Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura.
    Hong H, Xiao W, Stempak LM, Sandhaus LM, Maitta RW.
    Transfusion; 2015 Apr; 55(4):756-65. PubMed ID: 25370931
    [Abstract] [Full Text] [Related]

  • 17. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R.
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [Abstract] [Full Text] [Related]

  • 18. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature.
    Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D.
    Transfusion; 2005 Jan; 45(1):41-9. PubMed ID: 15647017
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.
    Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG.
    Transfusion; 2006 Oct; 46(10):1693-704. PubMed ID: 17002625
    [Abstract] [Full Text] [Related]

  • 20. Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma.
    Sidhu D, Snyder EL, Tormey CA.
    J Clin Apher; 2017 Jun; 32(3):158-162. PubMed ID: 27246502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.